Making COVID-19 clinical trials work with the help of the VCU Wright Center: The remdesivir story

remdesivir establishing a standard of care for COVID-19

This story was initially published as a feature in the spring issue of the MCV Foundation's NEXT magazine and is excerpted on its website.

Arun Sanyal, M.D., describes the early part of 2020 like seeing, without any defenses in place, an army advance around the globe toward Richmond.

arun sanyal

VCU Wright Center researcher Arun Sanyal, M.D., a liver specialist and gastroenterologist at VCU Health, played an instrumental role in bringing clinical trials for the antiviral drug remdesivir to VCU Health. Since then, the drug has become a standard of care for COVID-19 patients. Photo: Allen Jones, VCU University Marketing

“As we were watching COVID-19 march through China, through Singapore, and then through Europe, we knew it was only a matter of time before it landed on our doorstep,” he said. “Then the first cases started occurring in the U.S., and I was concerned that we would have a large number of cases without any real evidence-based medicine to tackle the problem.”

Dr. Sanyal, a liver specialist and gastroenterologist at VCU Health, started exploring opportunities to bring possible treatments to VCU Health, and he found that an antiviral drug called remdesivir seemed promising. It had been used in previous SARS (severe acute respiratory syndrome) outbreaks and to fight Ebola. The research and data was limited because of the relative speed at which Ebola was contained, but there was enough preliminary data to make a clear-cut rationale for remdesivir’s use, to see some signs it might be effective, and to know that it was safe.

A company called Gilead Sciences manufactures remdesivir, and in early spring it was selecting sites for the global trial testing the drug’s efficacy against COVID-19. Dr. Sanyal had previously conducted many trials related to liver disease for the company, so he gave them a call.

“I told them that, as a major academic health center in Central Virginia, we are care providers to many people,” he said. “While the rest of the country was just throwing whatever came to mind at the patient, hoping something would work — which is sort of like throwing a stone in the dark and hoping you’ll hit something or someone — we needed a more targeted approach. Gilead ended up taking us on as a site.”

CLINICAL TRIALS: A TARGETED APPROACH TO TREATMENT

Dr. Sanyal and his team participated in two trials that enrolled participants with documented COVID-19 infection who had fever and symptoms warranting hospitalization. Doctors at VCU Health administered remdesivir intravenously in five- or 10-day regimens and followed up 28 days later.

To make remdesivir available to patients through this trial, the VCU Health team worked exceptionally fast. “From the first phone call to actually enrolling our first patient was five days,” Dr. Sanyal said. “That process would normally take three to six months. It goes to show how when everybody is aligned with a mission just how fast things can move.”

The team included physicians, pharmacists, nursing specialists and support staff, and there were daily calls in the mornings and in the afternoons to review every case that came in and make sure all patients who might benefit were included. “This all happened at the early stage of COVID where we were still learning how to keep ourselves safe while taking care of patients,” Dr. Sanyal said. “We also were training the nursing staff on the floors how to administer study drugs, do it correctly and safely, and complete all the documentation needed to make sure we were compliant with federal regulations while treating a very sick population.”

This seamlessly integrated approach is something that Dr. Sanyal said makes VCU Health a special place. “There is an established infrastructure here for doing patient-oriented research,” he said. “We have, through the Wright Center for Clinical and Translational Research, a very well established mechanism to evaluate all of the different research ideas that come through and to be able to evaluate them to see which have the greatest scientific and clinical merit, evaluate their feasibility and safety, and then create prioritization schemes to decide what treatments we want to take on. We have a lot of experience and expertise in taking on diseases for which no one has answers, finding the answers, then bringing them back so the rest of the world can use them.”

A FAST-TRACKED TREATMENT

The remdesivir studies at VCU Health concluded in May, and the early nationally aggregated results showed enough promise to make it one of the first treatments for COVID-19 to receive an emergency use authorization from the U.S. Food and Drug Administration. This made the drug available to patients across the country, and it became part of the standard of care.

“Here at VCU, what we did was help translate research into an evidence-based drug that is available not just in the U.S., but around the world for patients with COVID,” Dr. Sanyal said. “The ideal approach in fighting COVID is to take a drug like remdesivir that attacks the virus, and to use another drug that helps reduce the immune reaction to the virus. Together, you can get both ends of the disease process.”

Publishing CTSA Program Hub’s Name
CTSA Program In Action Goals
Goal 2: Engage Patients and Communities in Every Phase of the Translational Process
Goal 4: Innovate Processes to Increase the Quality and Efficiency of Translational Research, Particularly of Multisite Trials